Los Angeles, California 90025

  • Analgesic Response

Purpose:

The aim of this study is to examine the effects of opioid analgesics on acute pain in participants maintained on buprenorphine+naloxone (Suboxone) for opioid use disorders. Seven medication conditions will be tested in a cold pressor test (CPT) paradigm.


Study summary:

Study design is a single-blind examination of the analgesic effects of a single dose of seven test medications provided in an experimental pain paradigm using a cold pressor test (CPT). Test medication conditions include buprenorphine, morphine, hydromorphone, hydrocodone, oxycodone, and two placebo conditions to match test medication formulations (oral tablet, sublingual tablet). Each medication condition will be tested on separate days (seven total days, completing within 12 weeks), with random assignment to order of study medications. After screening, eligible participants will be scheduled for 7 days of testing with test days at least 3 days apart to provide a sufficient medication wash-out period. Pain testing will utilize cold pressor tests (CPT), in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance. Participants will be given a practice trial to provide familiarity with the test and reduce test anxiety. Two CPTs will occur on each test day, and pre- and post-CPT assessments will be administered. Blood samples will be taken on each test day to measure blood levels of buprenorphine. Daily procedures include: (1) A baseline CPT (BL-CPT), (2) Administration of the test medication (active drug or placebo), (3) CPT administered at the time of maximum drug effect (Tmax-CPT) specific to medication (range 30-120 minutes), (4) Pupillometry conducted at baseline (before BL-CPT), and at time of maximum drug effect (before Tmax-CPT). Each participant will be discharged after clinical determination of the participant's safety and well-being. Testing will continue until twelve trials of each medication condition are completed.


Criteria:

Inclusion Criteria: 1. Male, in good general health 2. 20-50 years old 3. Fluent in English 4. Maintained on buprenorphine for at least 3 months 5. Able to complete testing/assessments for 7 test days within 12 weeks 6. Approved for participation by buprenorphine-prescribing physician Exclusion Criteria: 1. Known hypersensitivity to any of the test opioids 2. Urine test positive for opioids (other than buprenorphine) or other illicit substances 3. Current use of any additional opioid or analgesic medication (other than buprenorphine), medical marijuana, MAOI, tricyclic antidepressant, duloxetine, gabapentin, pregabalin, or other medication considered unsafe or having potential to influence pain perception as determined by study physician. 4. Presence of acute pain condition or planned surgery during the study period 5. Unstable vital signs as determined by the study physician. 6. Current pattern of alcohol, benzodiazepine, or other sedative hypnotic use, as determined by the study medical clinician, which would preclude safe participation in the study; 7. Pending legal action or other situation that might prevent remaining in the area for the duration of the study 8. Current medical or psychiatric condition that could detract from study objectives, place the participant at risk, or interfere with treatment goals


NCT ID:

NCT02136784


Primary Contact:

Principal Investigator
Walter Ling, MD
University of California, Los Angeles

Jessica Jenkins, MA
Phone: 310-267-5318
Email: jenkinsj@ucla.edu


Backup Contact:

Email: hillhous@ucla.edu
Maureen Hillhouse, PhD
Phone: 310-267-5308


Location Contact:

Los Angeles, California 90025
United States

Jessica Jenkins, MS
Phone: 310-267-5318
Email: jenkinsj@ucla.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.